Intravenous ketamine infusion for a patient with treatment‐resistant major depression: a 10‐month follow‐up

Summary What is known and objective Ketamine in a subanaesthetic dose has been shown to produce rapid antidepressant effects. Here, we describe a long‐term follow‐up case of a Korean patient with severe major depression who received repeated ketamine intravenous therapy (KIT). Case description A 49‐...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical pharmacy and therapeutics Vol. 43; no. 4; pp. 581 - 583
Main Authors Kwon, J. H., Sim, W. S., Hong, J. P., Song, I. S., Lee, J. Y.
Format Journal Article
LanguageEnglish
Published England Hindawi Limited 01.08.2018
Subjects
Clinical trials
Intravenous administration
intravenous infusion
Ketamine
major depression
Mental depression
Mood
Patients
intravenous infusion
ketamine
major depression
Online AccessGet full text

Cover

More Information
Summary:Summary What is known and objective Ketamine in a subanaesthetic dose has been shown to produce rapid antidepressant effects. Here, we describe a long‐term follow‐up case of a Korean patient with severe major depression who received repeated ketamine intravenous therapy (KIT). Case description A 49‐year‐old woman with a 6‐year history of treatment‐resistant major depression was given KIT once every 1 or 2 weeks over 10 months, for a total of 36 treatments. Her mood stabilized, and she showed a nearly 50% reduction in the severity of her depressive symptom. What is new and conclusion Long‐term repeated KIT may be an option for alleviating treatment‐resistant and relapsing major depression. Further research and large clinical trials are needed on the optimum KIT protocol, including dose, dosing interval, total number of treatments and when to stop.
ISSN:0269-4727
1365-2710
DOI:10.1111/jcpt.12669